Edith Cowan University

Research Online
Research outputs 2022 to 2026
2-16-2022

Adverse events reporting of clinical trials in exercise oncology
research (ADVANCE): Protocol for a scoping review
Hao Luo
Edith Cowan University, h.luo@ecu.edu.au

Oliver Schumacher
Edith Cowan University, o.schumacher@ecu.edu.au

Daniel A. Galvão
Edith Cowan University, d.galvao@ecu.edu.au

Robert U. Newton
Edith Cowan University, r.newton@ecu.edu.au

Dennis R. Taaffe
Edith Cowan University, d.taaffe@ecu.edu.au

Follow this and additional works at: https://ro.ecu.edu.au/ecuworks2022-2026
Part of the Clinical Trials Commons, Diseases Commons, and the Oncology Commons
10.3389/fonc.2022.841266
Luo, H., Schumacher, O., Galvão, D. A., Newton, R. U., & Taaffe, D. R. (2022). Adverse Events Reporting of Clinical
Trials in Exercise Oncology Research (ADVANCE): Protocol for a Scoping Review. Frontiers in oncology, 12, 841266.
https://doi.org/10.3389/fonc.2022.841266
This Journal Article is posted at Research Online.
https://ro.ecu.edu.au/ecuworks2022-2026/400

METHODS
published: 16 February 2022
doi: 10.3389/fonc.2022.841266

Adverse Events Reporting of
Clinical Trials in Exercise Oncology
Research (ADVANCE): Protocol for
a Scoping Review
Hao Luo 1,2*, Oliver Schumacher 1,2, Daniel A. Galvão 1,2, Robert U. Newton 1,2
and Dennis R. Taaffe 1,2
1 Exercise Medicine Research Institute, Edith Cowan University, Joondalup, WA, Australia, 2 School of Medical and Health
Sciences, Edith Cowan University, Joondalup, WA, Australia

Edited by:
Nicola Fusco,
University of Milan, Italy
Reviewed by:
Marco Invernizzi,
University of Eastern Piedmont, Italy
Alessandro de Sire,
University of Magna Graecia, Italy
*Correspondence:
Hao Luo
hluo1@our.ecu.edu.au
Specialty section:
This article was submitted to
Cancer Epidemiology and Prevention,
a section of the journal
Frontiers in Oncology
Received: 22 December 2021
Accepted: 18 January 2022
Published: 16 February 2022
Citation:
Luo H, Schumacher O,
Galvão DA, Newton RU and
Taaffe DR (2022) Adverse Events
Reporting of Clinical Trials in Exercise
Oncology Research (ADVANCE):
Protocol for a Scoping Review.
Front. Oncol. 12:841266.
doi: 10.3389/fonc.2022.841266

Frontiers in Oncology | www.frontiersin.org

Introduction: Adequate, transparent, and consistent reporting of adverse events (AEs) in
exercise oncology trials is critical to assess the safety of exercise interventions for people
following a cancer diagnosis. However, there is little understanding of how AEs are
reported in exercise oncology trials. Thus, we propose to conduct a scoping review to
summarise and evaluate current practice of reporting of AEs in published exercise
oncology trials with further exploration of factors associated with inadequate reporting
of AEs. The study ﬁndings will serve to inform the need for future research on
standardisation of the deﬁnition, collection, and reporting of AEs for exercise
oncology research.
Materials and Methods: The ADVANCE (ADverse eVents reporting of clinicAl trials iN
exerCise oncology rEsearch) study will be conducted and reported following the PRISMA
extension for scoping reviews guideline. Any type of clinical trial involving an exercise
intervention in people living with and beyond cancer with a full-text report in English will be
included. Six electronic databases (Embase, PubMed, Google Scholar, Web of Science
Core Collection, SPORTDiscus, and CINAHL Plus) will be searched for studies. Two
independent review authors will assess eligibility of identiﬁed studies, chart data using preestablished extraction forms, and evaluate adequacy of reporting of AEs-related data
against a 20-item scoring checklist derived from the CONSORT (Consolidated Standards
of Reporting Trials) harms extension. We will summarise results using descriptive and
inferential analysis methods.
Ethics and Dissemination: No ethics approval will be required to conduct the
ADVANCE study owing to inclusion of only published data. The study results will be
disseminated via publications in peer-reviewed journals and presentations at national and
internationa conferences.
Systematic Review Registration: Open Science Framework: https://osf.io/NXEJD/
(doi:10.17605/OSF.IO/NXEJD).
Keywords: adverse events, completeness of reporting, exercise, harms, knowledge synthesis, oncology
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will serve to inform the need for the development of consensus
guidelines speciﬁc to clinical exercise trials in oncology for the
deﬁnition, collection, and reporting of AEs.

INTRODUCTION
Exercise is emerging as a therapy in supportive oncology care for
people living with and beyond cancer (1). There is substantial
evidence that exercise can provide an abundance of beneﬁts,
including improving physical structure and function, cancerrelated fatigue, psychological distress and quality of life (2–5),
increasing resilience prior to surgery and rehabilitation after
surgery, as well as reducing disease speciﬁc and overall mortality
risk (6, 7). In this context, accurate knowledge of safety proﬁles of
exercise interventions is crucial for health policy makers and
healthcare providers to critically appraise the utility of an
exercise intervention and can facilitate informed decision
making for cancer patients and survivors considering exercise
therapy. Lack of conﬁdence in ﬁndings of harms from clinical
exercise trials can hinder implementation of exercise therapy as
part of standard oncology care (1, 8, 9). This is particularly true for
people with an aggressive malignancy (e.g., pancreatic ductal
adenocarcinoma), advanced disease, and/or older age as well as
patients during active oncological treatments, where safety
concerns of exercise may be more prominent (9–11). Thus,
complete and clear reporting of adverse events (AEs) in exercise
oncology trials is warranted for the purpose of identifying and
quantifying potential harms of exercise interventions.
Exercise has been repeatedly reported as a safe intervention
strategy in people following a cancer diagnosis regardless of age,
disease type and stage, and oncological treatment (11–15).
However, these ﬁndings may be related to the absence of or
inadequate analysis and presentation of AEs data in reports of
exercise oncology studies. For example, systematic reviews and
meta-analyses examining safety of exercise interventions in adult
cancer patients and survivors indicated that up to 60% of the
included studies made no mention of AEs (i.e., whether or not
there was an AE) (11, 13–16). In addition, data for health-related
withdrawals and discontinuations is an important source of
information on potential harms of healthcare interventions
(17, 18). Nevertheless, exercise researchers often neglect to
report and categorise such data as AEs in their trial reports
(including studies in cancer patients and survivors) (11, 19),
suggesting understatement and incomplete reporting of AEs. Of
importance, methods for deﬁnition, collection and reporting of
AEs have not yet been standardised for exercise oncology trials,
which can limit current safety ﬁndings in this ﬁeld (1, 20).
Although AEs reported in exercise trials for people following
a cancer diagnosis (mostly breast) have been extensively
examined (11–16), there is little understanding of the methods
used for deﬁning, collecting, presenting and analysing AEs and
the patterns of reporting of AEs data in exercise oncology trials.
Additionally, the completeness of reporting of AEs-related data
have not yet been evaluated objectively. Therefore, we propose to
undertake a scoping review to identify and map published trials
of exercise interventions in people following a cancer diagnosis
reporting AEs, and summarise their characteristics of reporting
of AEs-related data. Further, we will quantify completeness of
AEs reporting, and explore factors associated with suboptimal
reporting of AEs. Results of the ADVANCE (ADverse eVents
reporting of clinicAl trials iN exerCise oncology rEsearch) study
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MATERIALS AND METHODS
The study protocol was developed following the Preferred Reporting
Items for Systematic reviews and Meta-Analyses extension for
Scoping Reviews (PRISMA-ScR) (21), and reported according to
the PRISMA-Protocols 2015 checklist (S1 Appendix) (22, 23). The
study is registered with Open Science Framework (OSF): https://osf.
io/NXEJD/ (doi:10.17605/OSF.IO/NXEJD).

Eligibility Criteria
We will use the following study characteristics and report
characteristics as criteria to select studies for the ADVANCE
study (Table 1).

Study Characteristics
Study Designs
We will include any type of interventional study design, including
randomised controlled trials (RCTs), non-RCTs, single-arm trials/
case series (24), and case reports. Observational study designs
where interventions were not assigned to participants by a study
investigator (25) will be excluded.

Participants
We will include studies in people following a cancer diagnosis,
regardless of their age, sex, cancer site, disease stage, and treatment
status (before, during or after any oncological treatment, such as
chemotherapy, radiotherapy, and surgery). Studies in mixed
cohorts of participants with or without an active/past
oncological condition will be excluded unless AEs data were
reported separately for involved cancer patients and survivors.

Interventions
Interventions of interest are any form of structured (planned,
individualised, and repetitive) exercise training that involves large
skeletal muscle groups and incorporates training stimuli in aerobic
ﬁtness, muscle strength/endurance/power, ﬂexibility, balance, and/
or coordination (26). These will include: (i) traditional resistance,
aerobic, and sensorimotor exercises, (ii) mind-body exercises (e.g.,
Qigong, Tai Chi, Yoga, and Pilates), (iii) sports (activities that
require physical effort and skills with predetermined rules and
objectives) and adapted sport activities (27), and (iv) video-game
based exercises. Multimodal interventions where exercise was
complemented by non-exercise components (e.g., dietary/
nutritional support and psychological counselling) will be
included. Moreover, interventions in which exercise was
performed along with an additional training modality (e.g.,
whole-body vibration and neuromuscular electrical stimulation)
will be included. There will be no restrictions on exercise settings
(e.g., clinics, gymnasiums/community areas, and homes) and
surroundings (i.e., on land or in water), supervision, delivery
mode (e.g., one-on-one, paired, and in a small group),
equipment, and prescriptions in terms of duration, frequency,
volume, intensity, and progression.
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TABLE 1 | An overview of eligibility criteria.
Categories

Inclusion criteria

Exclusion criteria

Study characteristics
Study designs
- Any type of interventional study design, including RCTs, non-RCTs, singlearm trials/case series, and case reports
Participants*
- People living with and beyond cancer
Interventions†

- Any form of planned, individualised and repetitive exercise training
(including structured walking exercise)

Comparators
Outcomes
Length of follow-up
Report characteristics
Language
Publication status
Year of publication
-

- Observational studies
- Mixed cohorts of participants with or without an active/past
oncological condition
- Non-recreational physical activity interventions (i.e., occupation,
transportation, and housework)
- Speciﬁc musculoskeletal rehabilitation interventions (e.g., pelvic
ﬂoor muscle exercises)
- Interventions used solely static muscle stretching

No restrictions
No restrictions on outcomes of interest or whether reporting AEs occurred
No restrictions
Only English
Only full text publications in peer-reviewed journals
No restrictions

*Studies in mixed cohorts of participants will be included when adverse events data were reported separately for cancer patients and survivors.
†
Studies using multimodal interventions in which exercise was complemented by non-exercise components (e.g., dietary/nutritional support) or performed with an additional training
modality (e.g., whole-body vibration) will be included.
AE, adverse event; RCTs, randomised controlled trials.

Report Characteristics

Any non-structured physical activity intervention and
interventions that used non-leisure-time physical activities (i.e.,
occupation, transportation, and housework) will be excluded.
We will also exclude interventions that focused on speciﬁc
musculoskeletal rehabilitation (e.g., pelvic ﬂoor muscle
exercises and swallowing exercises) and/or used exclusively
static muscle stretching. Walking will be considered as an
aerobic-based exercise when it was individually tailored and
used appropriately.

We will only include full-text reports that were written in English
and published in peer-reviewed journals. There will be no
restrictions placed on year of publication.

Information Sources
To ensure transparency and maximise reproducibility of literature
searches, we will follow the PRISMA extension for literature
search in reporting search components for this review (29). We
will search six databases from the date of inception, including
PubMed, Embase (Embase.com), Web of Science Core Collection
(webofknowledge.com), Google Scholar, SPORTDiscus
(EBSCOhost), and CINAHL Plus (EBSCOhost). As the
ADVANCE study will focus exclusively on published exercise
oncology trials and the reporting practice for AEs-related data, we
will not adopt any additional information source (e.g., grey
literature and contacting authors of included trials).

Comparators
Given that different types of interventional study designs will be
included, we will not select studies based on whether there is a
comparator or what comparative interventions were used.

Outcomes
To provide a comprehensive overview regarding current practice
of AEs reporting, we will not select studies based on reported
outcome measures. With regard to AEs, we will consider any
harmful outcome that occurred over the course of the trial
(including the follow-up period after the prescribed exercise
intervention) and was explicitly reported in the included trial
reports, irrespective of the relatedness to the exercise
intervention undertaken. This is to take account of potential
variations in the deﬁnition of an AE in current exercise oncology
research and the fact that determination of relatedness of AEs to
the prescribed intervention is largely subjective and with
unknown validity (17, 28). In addition, occurrence of healthrelated withdrawals and discontinuations will be considered as
AEs. Similarly, occurrence of non-attendance, nonadherence and
intolerability to exercise interventions/testing due to health
reasons will also be considered as AEs.

Search Strategy
Literature search strategies will be developed by the review team,
which will be reviewed by a subject librarian at Edith Cowan
University (ECU) and reﬁned accordingly. Detailed search
strategies of all selected databases will be provided in the ﬁnal
reports of the study. A draft search strategy for PubMed is provided
in S2 Appendix. Only thesaurus and free-text terms related to
‘cancer’ and ‘exercise’ will be used in electronic searches. Given the
databases selected and relatively broad search terms to be used, the
planned electronic searching will provide sufﬁcient evidence for
the study. As a result, we will not employ any additional search
method to identify studies (e.g., citation searching).

Study Selection

Length of Follow-Up

Records yielded from database searching will be exported and
stored in Covidence (Veritas Health Innovation Ltd, Melbourne
VIC, Australia). Only the maximum number of results that can be

There will be no restrictions on the length of follow-up post
exercise intervention.
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and S4 Appendix). These items will address various aspects of
AEs reporting in different sections of a paper from the title/
abstract to the discussion section. Speciﬁcally, information will
be captured regarding (i) whether or not mentioning of AEs in
the title/abstract (item 1) and the introduction section (item 2),
(ii) approaches to deﬁnition, collection, presentation and
analysis of AEs (items 3a-5), (iii) appropriateness in
describing AEs results (including health-related withdrawals
and discontinuations, and tolerability of exercise training/
testing) (items 6a-9), and (iv) whether or not there was a
discussion of AEs ﬁndings (items 10a-10c). When pertinent,
each item will be rated as ‘yes’ or ‘no’ depending on whether or
not the information was reported properly in the speciﬁed
section. Similar to previous studies that used the CONSORT
harms criteria appraising quality of reporting of AEs in clinical
trials (31, 33, 34), a score of 1 or 0 will be given to items rated as
‘yes’ or ‘no’ with equal weight attributed to each item. As such,
the completeness of reporting of AEs-related data for a trial
report will be determined by a sum score calculated based on the
applicable items in the checklist with higher scores indicating
greater data adequacy.
Additionally, we will quantify the relative emphasis given to
reporting of AEs in included RCTs using the method
recommended by Ioannidis et al. (30, 35). This approach
has been widely used by others as an objective measure
complementary to quality assessment of reporting of AEs in
RCTs (36–38). Speciﬁcally, we will calculate the extent of printed
space dedicated to reporting of AEs in the results section and the
proportion it represents of the entire results section. The printed
space occupied by AEs data in the results section will be
calculated as S/(N×Y) pages, where S is the length in
centimeters of the results section for reporting of AEs, N is the
number of columns on a printed page, and Y is the length in
centimeters of the print area on a page (excluding upper and
lower margins). Where available, subheadings concerning AEs
[e.g., “Safety, tolerance, and attendance of the exercise program”
(39)] will be included in the space calculation. All measurements
will be performed using the Measuring Tool in Adobe Acrobat
Reader DC (Adobe Inc., San Jose, CA) and reported with a 0.05page resolution. Further, the number of tables and ﬁgures
devoted to or containing AEs data in included RCTs will be
recorded (including any presented in Supplementary Materials);
however, the space occupied by tables and ﬁgures will not be
included in the calculations described above.

displayed in Google Scholar for a particular search query (up to n =
1000) will be screened (29). Duplicates will be removed either
automatically (using Covidence) or manually. After de-duplication,
two independent reviewers will select studies against the eligibility
criteria. At the title and abstract screening stage, records will only be
excluded if explicitly identiﬁed as: (i) editorials, commentaries, and
letters, (ii) non-experimental (including reviews/meta-analyses,
study protocols, observational studies (25), and qualitative
studies) and preclinical studies, or (iii) delivering no exercise
interventions or exercise as a subordinate intervention. This is to
prevent exclusion of records where AEs were not addressed in titles
and abstracts of included trial reports. For studies with duplicate
publications reporting AEs, if the number of participants reported
was different across publications, the article involving the highest
number of participants will be considered as the main report and
thus included; when the number of participants was reported
consistently across different trial reports, we will refer to the ﬁrst
article resulting from the trial. In addition, we will refer to the ﬁrst
article when none of the resultant publications of a trial reported
AEs. However, if trials with duplicate publications only addressed
AEs in one of the reports, this report will be included regardless of
the number of participants involved or date of publication. Any
disagreement will be addressed through discussion between the two
review authors or (if needed) adjudication by a third reviewer.

Data Extraction and Evaluation of
Completeness of AEs Reporting
Two independent reviewers will chart data from included trial
reports using pre-established, structured extraction forms that will
be piloted and reﬁned accordingly to ensure all relevant data can
be captured. Any discrepancy will be resolved through discussion
between the two reviewers or (if needed) adjudication by a third
reviewer. Draft data extraction forms are provided in Tables 2, 3.
In addition, elaboration and explanation documents for the forms
will be provided to minimise inconsistencies in data extraction
(S3, S4 Appendixes).
We will extract trial parameters that may affect reporting of
AEs for all included trials (Table 2 and S3 Appendix) (30–32),
including: (i) general publication information (year of
publication, journal impact factor, and trial funding), (ii) study
characteristics (trial location, study design, nature of controls (if
applicable), trial phase (if applicable), study setting (i.e., singleor multi-centre), and whether or not study of AEs was a primary
outcome), (iii) participant characteristics (sample size, age,
cancer site, disease stage, and cancer treatment status), and
(iv) characteristics of the exercise intervention (mode, length
of intervention, frequency, session duration, intensity,
and supervision).
Whether there was reporting of AEs in the included studies
will be recorded as ‘Yes’, ‘No’, or ‘Yes, but only as generic
statements’ (e.g., “no serious AEs occurred” or “the exercise
program was generally safe and well tolerated”). For studies
identiﬁed as ‘Yes’ (including studies that reported AEs in generic
statements), we will further extract data pertinent to AEs using a
20-item checklist derived from the 10 recommendations in the
CONSORT (Consolidated Standards of Reporting Trials)
extension for reporting of harms-related data (17) (Table 3

Frontiers in Oncology | www.frontiersin.org

Critical Appraisal of Included Studies
We will not appraise methodological quality or risk of bias of
included studies to provide a comprehensive overview of AEs
reporting in current exercise oncology trials. This is consistent
with the PRISMA-ScR statement considering critical appraisal of
individual sources of evidence as an optional step (21).

Data Analysis
We will use Cohen’s kappa coefﬁcient (40) with 95%
conﬁdence intervals to assess inter-rater reliability of study
selection and data extraction. The total number of studies that
reported AEs will be counted and the proportion of studies
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TABLE 2 | Data extraction form for trial parameters.
Title of trial report:
Name of lead author:
General publication information
1. Year of publication
2. Journal impact factor
3. Trial funding
Study characteristics
4. Trial location

5.

Study design

6.

Comparators/Controls*

7.

Trial phase†

8. Study setting
9. Adverse events as a primary study outcome
Participant characteristics
10. Sample size
11. Participant age
12. Primary cancer diagnosis

13. Disease stage‡
14. Cancer treatment

Exercise intervention characteristics
15. Exercise mode

16. Program duration
17. Exercise frequency
18. Session duration
19. Exercise intensity
20. Supervision

(_______)
Journal name:
□<3
□ Yes

□ 3-7

□>7
□ No

□ N/A

□ United States of America
□ Australia
□ Other (_______)

□ Canada
□ United Kingdom
□ International collaboration

□ Randomised controlled trial
□ Single group trial or case series
□ Active
□ Usual care
□ Phase 0 (pilot study)
□ Phase II
□ Not speciﬁed
□ Single-centre
□ Yes

□ Non-randomised controlled trial
□ Case report
□ Sham
□ N/A
□ Phase I
□ Phase III
□ N/A
□ Multi-centre
□ No

n = (_______)
□ < 14 years
□ ≥ 65 years
□ Breast
□ Colorectal
□ Other (_______)
□ In situ
□ Distant
□ Before treatment/Active surveillance
□ On-treatment (_______)
□ Not speciﬁed

□ 15-39 years
□ Mixed
□ Lung
□ Prostate
□ Mixed cohorts (_______)
□ Localised
□ Mixed (_______)

□ 40-64 years
□ Not speciﬁed

□ Regional
□ Not speciﬁed

□ Off-treatment (_______)

□ Aerobic exercise only (including walking)
□ Resistance training only
□ Combined aerobic and resistance training
□ Multimodal intervention (_______)
□ Mind-body exercise (_______)
□ Sport activities (_______)
□ Video game-based exercise
□ Other (_______)
□ < 12 weeks
□ 12-24 weeks
□ > 24 weeks
□ Not speciﬁed
□ 1 session/week
□ 2-3 sessions/week
□ > 3 sessions/week
□ Not speciﬁed
□ < 30 minutes/session
□ 30-60 minutes/session
□ > 60 minutes/session
□ Not speciﬁed
□ Low-Moderate
□ Moderate-Vigorous
□ Vigorous
□ Not speciﬁed
□ Fully supervised
□ Partially supervised

□ No supervision

*This item is not applicable to single-arm trials/case series and case reports.
†
This item is not applicable to case reports.
‡
Studies that included participants with hematological or brain/central nervous system cancers, disease stage (if reported) will be recorded separately as stated in the included trial report
owing to different staging systems used.
N/A, not applicable.

Independent samples t-test or one-way analysis of variance
will be performed to compare the mean number of items met in
the checklist (i.e., mean sum score) between groups of studies of a
speciﬁc study design (e.g., funded RCTs vs. unfunded RCTs). In a
similar fashion, the extent of printed space for AEs reporting in
the results section and the proportion it represents of the entire
results section in RCTs with different trial characteristics will be
compared. Given that the checklist items in title/abstract,

reporting AEs will be summarised as per study design (i.e.,
RCTs, non-RCTs, single-group trials/case series, and case
reports). In addition, the number of items met in the
checklist (Table 3) for studies of a speciﬁc category (as per
trial characteristics), and the extent of printed space dedicated
to AEs reporting in the results section and the proportion it
represents of the entire results section in RCTs will be
analysed descriptively.

Frontiers in Oncology | www.frontiersin.org
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TABLE 3 | Adverse events-related data extraction form.
Title of trial report:
Name of lead author:
Paper
section

Item
no.

CONSORT harms recommendations

Title and abstract
1
If the study collected data on harms and beneﬁts,
the title or abstract should so state.

Introduction
2

Checklist for reporting of adverse events-related data

1. If the study of harms was a primary outcome, did the title
mention the word ‘harms’ or related terms/phrases or a speciﬁc
event of interest, or was the information on harms presented in the
abstract (including generic statements, e.g., “no adverse events
occurred”)?
If yes, please indicate where: title or abstract or both.

Rating
(Y=1, N=0)

If yes,
provide
page
no.

Y

N NA

□

□ □

(_______)

If the trial addresses both harms and beneﬁts, the 2. If the trial intended to investigate both harms and beneﬁts, was
introduction should so state.
there a balanced presentation of possible beneﬁts and harms of
exercise for cancer patients and survivors in the Introduction
section?

□

□

□

List addressed adverse events with deﬁnitions for
each (with attention, when relevant, to grading,
expected vs. unexpected events, reference to
standardized and validated deﬁnitions, and
description of new deﬁnitions).

□

□

□

□

□

□

□

□

□

□ □

Methods
3

4

Clarify how harms-related information was
collected (mode of data collection, timing,
attribution methods, intensity of ascertainment,
and harms-related monitoring and stopping rules,
if pertinent).

5

Describe plans for presenting and analysing
information on harms (including coding, handling
of recurrent events, speciﬁcation of timing issues,
handling of continuous measures, and any
statistical analyses).

6

Describe for each arm the participant withdrawals
that are due to harms and the experience with
the allocated treatment.

3a. Did the author(s) deﬁne the types of adverse events intending
to monitor or the recorded adverse events for the study?
If yes, please indicate if the used deﬁnition and grading criteria
was validated (reference to the source document) or non-validated
(provision of new deﬁnition and description of validation process).
3b. Did the author(s) clarify if the reported adverse events included
all the adverse events collected or a selected sample?
If a selected sample, was an explanation provided as to how,
why, and who selected adverse events for reporting (answer
Complete, Partial or None depending on the adequacy of
information provided)?
3c. Were the author(s) explicit about separately reporting expected
and unexpected adverse events?
4a. Was the mode of adverse events collection speciﬁed (i.e.,
active vs. passive surveillance of harms)?
If yes, please indicate whether: active or passive or both.
4b. Was the time frame of monitoring for adverse events reported?
4c. If relatedness of collected adverse events to the exercise
intervention/testing or cancer treatments undertaken was
assigned, did the author(s) specify the attribution process?
4d. Did the author(s) specify rules to discontinue allocated exercise
intervention for harms-related reasons?
5. Did the author(s) report plans for presenting and analysing
adverse events data?

(_______)

□
(_______)

(_______)
□
□ □
□
□ □

□

□ □

□

□ □

□

□ □

□

□ □

□

□ □

□

□ □

□

□ □

Results

7

8

6a. Did the author(s) report the number of participants who
withdrew due to adverse events (including death) appropriately?
6b. Did the author(s) report the number of participants who
discontinued or were not adherent to the allocated exercise
intervention due to adverse events appropriately?
6c. If there was reporting of withdrawals or discontinuations due to
adverse events, did the author(s) report their timing of occurrence
appropriately?
Provide the denominators for analyses on harms. 7. If there were analyses of adverse events data, did the author(s)
specify the denominators (i.e., the total number of participants and
total follow-up time included in each analysis)?
Present the absolute risk of each adverse event
8a. If there were adverse events, did the author(s) report the
(specifying type, grade, and seriousness per arm), incidence or frequency for each type and severity category (if
and present appropriate metrics for recurrent
relevant) of adverse event appropriately?Alternatively, if there were
events, continuous variables and scale variables, no adverse events of a speciﬁc type and severity, did the author(s)
whenever pertinent.
so state?

(Continued)
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TABLE 3 | Continued
Title of trial report:
Name of lead author:
Paper
section

Item
no.

9
Discussion
10

CONSORT harms recommendations

Describe any subgroup analyses and exploratory
analyses for harms.
Provide a balanced discussion of beneﬁts and
harms with emphasis on study limitations,
generalizability, and other sources of information
on harms.

Checklist for reporting of adverse events-related data

Rating
(Y=1, N=0)

Y

N NA

*8b. Did the author(s) report the number of affected participants for
each type and severity category (if relevant) of adverse event
appropriately?
*9. If analyses of adverse events were performed, did the author(s)
report any subgroup or exploratory analysis ﬁndings?

□

□ □

□

□ □

10a. If the author(s) intended to investigate both harms and
beneﬁts or reported occurrence of adverse events, was there a
balanced discussion on efﬁcacy and harms (including no adverse
events occurred) ﬁndings of the exercise intervention?
†
10b. If there was intention to investigate harms of an exercise
intervention, did the author(s) discuss study limitations speciﬁc to
adverse events ﬁndings (e.g., inconclusive ﬁndings, lack of power,
lack of generalisability, etc)?
10c. If the author(s) intended to investigate both harms and
beneﬁts or reported occurrence of adverse events, was there a
discussion of any previous evidence on harms ﬁndings of exercise
in cancer patients and survivors (including data derived from a pilot
study of the exercise intervention)?

□

□ □

□

□ □

□

□ □

If yes,
provide
page
no.

Modiﬁed from: Ioannidis JP, Evans SJ, Gotzsche PC, O’Neill RT, Altman DG, Schulz K, Moher D, CONSORT Group. Better reporting of harms in randomized trials: an extension of the
CONSORT statement. Ann Intern Med. 2004;141:781-788.
*Item not required for case reports.
†
Item not required for studies that did not have concurrent controls, including single-arm trials/case series and case reports.
N, no; Y, yes; NA, not applicable.

introduction and discussion sections are optional, we will
perform subgroup analyses of the completeness of AEs
reporting (as per mean sum score) for RCTs and non-RCTs
that were intended for both harms and efﬁcacy outcomes or for
efﬁcacy outcomes alone.
Logistic regression will be performed to examine whether
there are any predictors of reporting of an individual item in
the checklist. This will be undertaken as per types of study
design. The predictors that will be considered in the analysis
include: year of publication, journal impact factor, trial
funding, trial location, type of control, participants
characteristics (including sample size, age, cancer site and
stage, and cancer treatment status), exercise interventions
characteristics (including mode, length, frequency, session
duration, intensity, and supervision), and whether or not
study of AEs was a primary outcome.
Statistical analyses will be performed using the latest version
of R available at the time of analysis (https://www.r-project.org/).
All tests will be two-tailed and a p-value ≤ 0.05 will be considered
statistically signiﬁcant.

the ADVANCE study. We will disseminate the study results via
publications in peer-reviewed journals and presentations at
national and international conferences. Additionally, ﬁndings
of the ADVANCE study will be discussed with relevant
stakeholders (including healthcare professionals, health policy
makers, exercise oncology researchers, and cancer patients and
survivors) to determine whether there is a need for the
development of guidelines for reporting of AEs speciﬁc to
exercise oncology trials.

DISCUSSION
Adequate, transparent, and consistent reporting of AEs in
exercise oncology trials is crucial to assess the safety of exercise
interventions in people living with and beyond cancer. However,
there is little knowledge with respect to how AEs are reported in
exercise oncology trials. To this end, the ADVANCE study is
proposed to review current practice of reporting of AEs in the
ﬁeld of exercise oncology.
There are several strengths for the ADVANCE study. First,
the study will include any type of interventional study design so
as to provide a comprehensive overview of reporting of AEs in
exercise oncology trials. Second, a pre-deﬁned scoring system
and an empirically-tested measure will be adopted to quantify
the completeness of AEs reporting in all included trials or the

Ethics and Dissemination
No ethics approval will be required to conduct the ADVANCE
study owing to inclusion of only published data. If there are any
modiﬁcations to the study protocol, they will be reﬂected in the
OSF registry (https://osf.io/NXEJD/) and in the ﬁnal reports for
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relative importance attached to reporting of AEs results in the
included reports for RCTs. Third, various analyses will be
performed to identify any trial-related parameters associated
with suboptimal reporting of AEs in order to formulate
suggestions for how to improve AEs reporting in future
exercise oncology trials. Lastly, studies will be identiﬁed
through rigorous searches in multiple broad disciplinary (i.e.,
Embase, PubMed, Web of Science Core Collection, and Google
Scholar) and subject-speciﬁc (i.e., SPORTDiscus and CINAHL
Plus) databases. The combination of these databases has been
shown to provide adequate and efﬁcient results for reviews on
the topics of allied health (41). A limitation of the ADVANCE
study is that only full-text trial reports written in English and
published in peer-reviewed journals will be included. However,
the evidence base derived from published trials in English would
be sufﬁcient to provide a comprehensive picture of current
practice of reporting of AEs in exercise oncology trials.
In conclusion, the ADVANCE study will be able to improve
our understanding of how AEs are reported and provide
directions for future research efforts to standardise reporting of
AEs in exercise oncology trials.
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